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PreviewExploiting Pseudomonas putida
for Drug Development
In this issue of Chemistry & Biology, a strategy that
combines large DNA fragment recombineering in
Escherichia coli and heterologous expression in
Pseudomonas putida is described. The work focuses
on myxochromide S, a natural compound produced
by Stigmatella aurantiaca.
An important source of drug leads is natural products. As
many as 60% of successful drugs are of natural origin,
and some of the most potent anticancer, antibacterial,
and antifungal drugs are natural products. The search
for novel natural compounds was very successful be-
tween 1940 and 1980. Automated instrument systems,
robots, and high-throughput screening platforms have
enabled the pharmaceutical industry to screen thou-
sands of microorganisms and plants for novel com-
pounds. Despite these efforts, the paucity of drug dis-
coveries since 1990 is coupled with the fact that natural
products are produced in small quantities in their native
hosts, making the drugs too expensive to harvest [1].
Approximately 20 years ago, scientists developed
methods to introduce DNA into Streptomyces species
[2]. A few years later, a new technology called combina-
torial biosynthesis was born [3]. In principle, this tech-
nology makes it possible to alter the structure of a
given molecule in the living organism, and even com-
plex structures can be modified that cannot be altered
by chemical synthesis. Since 1999, drug discovery stra-
tegies for pharmaceutical applications have been expe-
riencing a revolutionary period. The completion of sev-
eral genome projects has provided thousands of
biosynthetic gene clusters of as yet unknown com-
pounds. More recently, genes and enzymes of these
clusters have been used for the generation of novel
compounds. Metabolic engineering has begun to have
an effect on natural product drug discovery in funda-
mentally new and practically useful ways. Metabolic
engineering involves much more than simply introduc-
ing genes into a cell—it often involves carefully balanc-
ing the genes in the new metabolic pathway so that no
gene is drastically overexpressed or underexpressed,
both of which prevent synthesis of the desired com-
pound. As such, the control of gene expression and the
control of metabolic flux balances is a core issue in the
production of drugs using metabolic engineering [4].
In this issue of Chemistry & Biology, Rolf Müller and
colleagues [5] describe a straightforward strategy that
makes possible the expression of a large biosynthetic
gene cluster in Pseudomonas putida. The group fo-
cused its work on myxochromide S, a natural com-
pound produced by the myxobacterium Stigmatella
aurantiaca. Myxochromides S are cyclic peptides con-
nected to unsaturated polyketide side chains [6].
Genes that are involved in the biosynthesis of these
compounds are large in size and together comprise
more than 60 kb. Müller’s group began their work byisolating a cosmid containing parts of the myxochrom-
ide biosynthetic gene cluster. Biosynthetic genes miss-
ing additional regulatory elements were then intro-
duced into the cosmid via genetic engineering using
the Red/ET recombination system. It is worthwhile to
mention that one of the regulatory elements was the
toluic acid–inducible Pm promoter, which was inserted
in front of the first gene of the cluster. All experiments
described so far were performed in Escherichia coli.
The engineered construct could then be transferred
into Pseudomonas putida, and after induction the re-
combinant strain was producing approximately 40 mg/l
myxochromide S, five times more than Stigmatella aur-
antiaca. The work performed by Müller’s group is open-
ing the door to a new chapter in natural product biology
and chemistry. A strategy is provided that promises to
express clusters of unknown function as discovered by
genome sequencing in many organisms and also to ex-
press large DNA fragments isolated from noncultivable
bacteria. In addition, this work will make it possible to
combine different gene clusters on one DNA fragment,
increasing the chance for the production of novel natu-
ral products.
There are a few issues not already discussed in the
study. The successful expression of biosynthetic gene
clusters in Streptomyces strains or even in E. coli have
been described in the past [7–9]. However, a general
method for the expression of gene clusters has never
been described, and, although data have not been pub-
lished, scientists all over the world have failed to do so
countless times. The challenge now for Müller’s group
will be to provide further successful examples and de-
scribe the limitations of this new technology.
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